Drug Trial Radar · NCT05929768
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,400
Planned (sponsor's estimate)
Start
Sep 15, 2023
Primary completion
Mar 31, 2033
Study completion Apr 2033
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jul 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Early Stage Triple-Negative Breast Carcinoma
Interventions
Biospecimen CollectionProcedure
Undergo collection of blood samples
CarboplatinDrug
Given IV
CyclophosphamideDrug
Given IV
DocetaxelDrug
Given IV
DoxorubicinDrug
Given IV
PaclitaxelDrug
Given IV
PembrolizumabBiological
Given IV
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Surgical ProcedureProcedure
Undergo surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Breast cancer event-free survival (BC-EFS)Time frame: Up to 5 years
Locations
963 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Recruiting
Anchorage Associates in Radiation Medicine
Anchorage, Alaska · Recruiting
Anchorage Radiation Therapy Center
Anchorage, Alaska · Suspended
Alaska Breast Care and Surgery LLC
Anchorage, Alaska · Recruiting
Alaska Oncology and Hematology LLC
Anchorage, Alaska · Recruiting
Alaska Women's Cancer Care
Anchorage, Alaska · Recruiting
Anchorage Oncology Centre
Anchorage, Alaska · Suspended
Katmai Oncology Group
Anchorage, Alaska · Recruiting
Providence Alaska Medical Center
Anchorage, Alaska · Recruiting
Fairbanks Memorial Hospital
Fairbanks, Alaska · Recruiting
Kingman Regional Medical Center
Kingman, Arizona · Recruiting
Cancer Center at Saint Joseph's
Phoenix, Arizona · Recruiting
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas · Recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Recruiting
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas · Recruiting
CARTI Cancer Center
Little Rock, Arkansas · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Highlands Oncology Group - Rogers
Rogers, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
Kaiser Permanente-Anaheim
Anaheim, California · Recruiting
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California · Recruiting
PCR Oncology
Arroyo Grande, California · Recruiting
Sutter Auburn Faith Hospital
Auburn, California · Recruiting
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California · Recruiting
Kaiser Permanente-Baldwin Park
Baldwin Park, California · Recruiting
Kaiser Permanente-Bellflower
Bellflower, California · Recruiting
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Recruiting
Tower Cancer Research Foundation
Beverly Hills, California · Recruiting
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California · Recruiting
Mills-Peninsula Medical Center
Burlingame, California · Recruiting
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California · Recruiting
Mercy Cancer Center - Carmichael
Carmichael, California · Recruiting
Mercy San Juan Medical Center
Carmichael, California · Recruiting
Eden Hospital Medical Center
Castro Valley, California · Recruiting
Sutter Davis Hospital
Davis, California · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
Mercy Cancer Center - Elk Grove
Elk Grove, California · Recruiting
Stanford Cancer Center Emeryville
Emeryville, California · Recruiting
Kaiser Permanente-Fontana
Fontana, California · Recruiting
Palo Alto Medical Foundation-Fremont
Fremont, California · Recruiting
Showing 40 of 963 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.